Literature DB >> 11606489

Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret.

M D Van Sickle1, L D Oland, W Ho, C J Hillard, K Mackie, J S Davison, K A Sharkey.   

Abstract

BACKGROUND & AIMS: Marijuana and other cannabinoids are effective anti-emetics. Despite ongoing controversy over their usage, the receptor distribution and the site of the anti-emetic action of these compounds are not known. Our aim was to investigate whether the cannabinoid 1 receptor (CB1r) and endocannabinoids play a role in the anti-emetic action of cannabinoids.
METHODS: Ferrets were given an emetic stimulus and the number of episodes of retching and vomiting were observed after administration of CB1r agonists and a CB1r antagonist. CB1r and fatty acid amide hydrolase (FAAH), which degrades endocannabinoids, were localized by immunohistochemistry.
RESULTS: CB1r and FAAH were localized in the dorsal vagal complex, consisting of the area postrema, nucleus of the solitary tract, and the dorsal motor nucleus of the vagus in the brainstem. CB1r was found in the myenteric plexus of the stomach and duodenum. Activation of CB1r by the agonists (delta)(9)-tetrahydrocannabinol, WIN 55,212-2, and methanandamide inhibited emesis and their action was reversed by a selective CB1r antagonist, which alone had no effect, but potentiated vomiting in response to an emetic stimulus.
CONCLUSIONS: CB1r mediates the anti-emetic action of cannabinoids in the dorsal vagal complex. Endocannabinoids are a novel neuroregulatory system involved in the control of emesis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11606489     DOI: 10.1053/gast.2001.28466

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  74 in total

Review 1.  Treating irritable bowel syndrome: overview, perspective and future therapies.

Authors:  Michael Camilleri
Journal:  Br J Pharmacol       Date:  2004-03-22       Impact factor: 8.739

Review 2.  Involvement of cannabinoid receptors in gut motility and visceral perception.

Authors:  Pamela J Hornby; Stephen M Prouty
Journal:  Br J Pharmacol       Date:  2004-04       Impact factor: 8.739

3.  Anandamide transport inhibition by ARN272 attenuates nausea-induced behaviour in rats, and vomiting in shrews (Suncus murinus).

Authors:  L D O'Brien; C L Limebeer; E M Rock; G Bottegoni; D Piomelli; L A Parker
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

4.  Effects of the FAAH inhibitor, URB597, and anandamide on lithium-induced taste reactivity responses: a measure of nausea in the rat.

Authors:  Shelley K Cross-Mellor; Klaus-Peter Ossenkopp; Daniele Piomelli; Linda A Parker
Journal:  Psychopharmacology (Berl)       Date:  2006-11-17       Impact factor: 4.530

5.  Dietary conditions and highly palatable food access alter rat cannabinoid receptor expression and binding density.

Authors:  Nicholas T Bello; Janelle W Coughlin; Graham W Redgrave; Ellen E Ladenheim; Timothy H Moran; Angela S Guarda
Journal:  Physiol Behav       Date:  2011-10-06

6.  Constitutive activity at the cannabinoid CB(1) receptor and behavioral responses.

Authors:  Katherine E Hanlon; Todd W Vanderah
Journal:  Methods Enzymol       Date:  2010       Impact factor: 1.600

7.  The effect of cannabidiol and URB597 on conditioned gaping (a model of nausea) elicited by a lithium-paired context in the rat.

Authors:  Erin M Rock; Cheryl L Limebeer; Raphael Mechoulam; Daniele Piomelli; Linda A Parker
Journal:  Psychopharmacology (Berl)       Date:  2007-11-09       Impact factor: 4.530

Review 8.  Endocannabinoids and the gastrointestinal tract: what are the key questions?

Authors:  G J Sanger
Journal:  Br J Pharmacol       Date:  2007-09-03       Impact factor: 8.739

9.  The FAAH inhibitor URB-597 interferes with cisplatin- and nicotine-induced vomiting in the Suncus murinus (house musk shrew).

Authors:  L A Parker; C L Limebeer; E M Rock; D L Litt; M Kwiatkowska; D Piomelli
Journal:  Physiol Behav       Date:  2009-02-23

Review 10.  Cannabinoids and GI Disorders: Endogenous and Exogenous.

Authors:  Zachary Wilmer Reichenbach; Ron Schey
Journal:  Curr Treat Options Gastroenterol       Date:  2016-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.